EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach

Antresa Jose, Abul Bashar Mohammad Kamrul-Hasan, Cornelius J Fernandez, Joseph M Pappachan

World Journal of Nephrology · 25.09.2026 · 15 (3)

DOI: 10.5527/wjn.120295 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Nephrology, online erschienen am 25.09.2026. Verfasst von Antresa Jose und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Mar Sleeva Medicity Pala 686584, Kerala, India. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the alarming rise in the global prevalence of the disease, type 2 diabetes mellitus (T2DM) has recently become the leading cause of chronic kidney disease (CKD) worldwide. Proteinuria, the earliest and common indicator of diabetic kidney disease (DKD), not only increases the risk of progression of CKD to end-stage renal disease (ESRD) but also multiplies the risk of cardiovascular (CV) disease in patients with diabetes. Medications such as angiotensin-converting enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and mineralocorticoid receptor antagonists (MRAs) have been shown to reduce proteinuria and therefore possess disease-modifying properties in patients with DKD. Clinical trials have demonstrated the efficacy of finerenone, a highly selective, non-steroidal MRA, in reducing renal and CV outcomes in patients with long-standing T2DM. The benefits of various SGLT-2is have also been observed in multiple studies. Therefore, a combination of these medications, with independent but complementary mechanisms of action, could provide superior benefits as add-on therapies to ACEis/ARBs rather than using either alone. This Opinion Review explores disease-modifying strategies in patients with DKD based on the most up-to-date evidence.

Schlagwörter

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetic kidney diseaseDisease-modifying treatmentMineralocorticoid receptor antagonistsRenin-angiotensin-aldosterone system

Autor:innen und Institutionen

  • Department of Endocrinology, Mar Sleeva Medicity Pala 686584, Kerala, India.
  • Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Bangladesh.
  • Department of Endocrinology and Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston PE21 9QS, Lincolnshire, United Kingdom.
  • Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, Greater Manchester, United Kingdom.
  • Department of Endocrinology and Metabolism, Countess of Chester Hospital NHS Trust, Chester CH2 1UL, Cheshire West and Chester, United Kingdom.
  • Department of Endocrinology and Metabolism, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal 576104, India. drpappachan@yahoo.co.in.

Zitieren

APA

Jose, A., Kamrul-Hasan, A. B. M., Fernandez, C. J., & Pappachan, J. M. (2026). Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. World Journal of Nephrology, 15(3). https://doi.org/10.5527/wjn.120295

Vancouver

Jose A, Kamrul-Hasan ABM, Fernandez CJ, Pappachan JM. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. World Journal of Nephrology. 2026;15(3). doi:10.5527/wjn.120295

BibTeX
@article{Jose2026,
  author = {Jose, Antresa and Kamrul-Hasan, Abul Bashar Mohammad and Fernandez, Cornelius J and Pappachan, Joseph M},
  title = {Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach},
  journal = {World Journal of Nephrology},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.5527/wjn.120295}
}
Kostenlos starten →